OncoMatch/Clinical Trials/NCT06386146
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Is NCT06386146 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including JAB-30355 and JAB-30355 for solid tumors.
Treatment: JAB-30355 · JAB-30355 — This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: TP53 y220c
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
lvef >50% assessed by echo or muga; qtcf ≤470 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Denver, Colorado
- Research site · Lake Mary, Florida
- Research site · St Louis, Missouri
- Research site · Canton, Ohio
- Research site · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06386146 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require TP53?
Yes, TP53 y220c is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify